Novel combination therapy shows promise for aggressive lymphoma resistant to immunotherapy

A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body’s natural response to viral infections, shows promising results in patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL), a rare and aggressive cancer with limited treatment options.

Facebook Comments